DEVELOPMENT OF ANALYTICAL METHOD FOR IMATINIB MESYLATE BY ULTRAVIOLET SPECTROSCOPY

  • AJITHKUMAR P Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Chidambaram, Tamil Nadu, India.
  • ANTON SMITH A Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Chidambaram, Tamil Nadu, India.

Abstract

Objective: A simple, selective, sensitive, specific, and spectrophotometric method has been developed for the detection of imatinib mesylate in pure form and formulations.


Methods: The analytical condition was optimized for the drug, carried out as per the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines.


Results: The drug shows absorption at 232.0 nm and obeyed beers law in the wide concentration range from 0.5 to 4.0 μg/ml. The lower limit of detection was found to be 0.331 μg/ml and the limit of quantification to be 1.004 μg/ml. The regression equation was found to be y = 0.08x. The precision of the method was found to be 99.04%±0.527% and the percentage of drug recovered by this method is 100.13%±1.375%.


Conclusion: The method is simple and suitable for determination for imatinib mesylate in pure and pharmaceutical preparation.

Keywords: Spectrophotometer, Imatinib mesylate, Determination

References

1. Sweetman SC. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009. p. 773-4.
2. Bende G, Kollipara S, Sekar V, Saha R. UV-spectrophotometric determination of imatinib mesylate and its application in solubility studies. Pharmazie 2008;63:641-5.
3. Camila T, Pedro LG, Fabio PG, Erika RM, Inês RM. Quantitative determination of nadolol in tablets by high-performance liquid chromatography and UV-derivative spectrophotometry. Anal Lett 2008;41:424-36.
4. Olajire A, Olakunle SI, Olaniyi AA. A new spectrophotometric method for the determination of nadolol. J Iran Chem Soc 2006;3:277-84.
5. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L, Gupta SK. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2004;804:431-4.
6. Vijayalakshmi R, Sri RN, Dhanaraju M. Method development for quantification of oxidation complexes of nadolol and resveratrol by visible spectrophotometry. Int J Pharm Pharm Sci 2014;7:304-7.
7. Kuna AK, Kumar KJ. RP-HPLC method development and validation of imatinib mesylate in tablet dosage form. Int J Pharm Pharm Sci 2011;3:39-44.
8. Amin AS, Ragab GH, Saleh H. Colorimetric determination of beta-blockers in pharmaceutical formulations. J Pharm Biomed Anal 2002;30:1347-53.
9. Eugene I. Colorimetric determination of nadolol in Tablets. J Pharm Sci 1978;67:1024-5.
10. Oostendorp RL, Beijnen JH, Schellens JH, Tellingen Ov. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomed Chromatogr 2007;21:747-54.
11. Patel BR, Kirschbaum JJ, Poet RB. High-pressure liquid chromatography of nadolol and other beta-adrenergic blocking drugs. J Pharm Sci 1981;70:336-8.
12. Chandana M. Method Development and validation for simultaneous estimation of nadolol and bendroflumethiazide in pharmaceutical dosage form by using RP-HPLC method. J Pharm Sci 2012;4:216-27.
13. Perlman S, Szyper M, Kirschbaum JJ. High-performance liquid chromatographic analysis of nadolol and bendroflumethiazide combination tablet formulations. J Pharm Sci 1984;73:259-61.
14. Ivanovic D, Medenica M, Jancic B, Malenovic A. Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in glivec capsules. J Chromatogr B Analyt Technol Biomed Life Sci 2004;800:253-8.
15. Solassol F, Bressolle L, Philibert V, Charasson C, Astre, F. Liquid chromatography-electrospray mass spectrometry determination of imatinib and it’s main metabolite, N-desmethyl- imatinib in human plasma. J Liq Chromatogr Relat Technol 2006;29:2957-74.
16. Vivekanand VV, Rao DS, Vaidyanathan G, Sekhar NM, Kelkar SA, Puranik PR. A validated LC method for imatinib mesylate. J Pharm Biomed Anal 2003;33:879-89.
17. Wahajuddin LN, Singh SP, Jain GK. Determination of lumefantrine in rat plasma by liquid-liquid extraction using LC-MS/MS with electrospray ionization: Assay development, validation and application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:1133-9.
18. Vivek R, Jose S. Development, evaluation and targeting of imatinib mesylate loaded solid lipid nanoparticles to the lymphatic system. Int J Pharm Sci Res 2018;9:2359-68.
19. European Medicines Agency. ICH Harmonized-Tripartite Guidelines, Validation of Analytical Procedure: Text and Methodology Q2 (R1); 2005.
Statistics
196 Views | 97 Downloads
Citatons
How to Cite
AJITHKUMAR P, and ANTON SMITH A. “DEVELOPMENT OF ANALYTICAL METHOD FOR IMATINIB MESYLATE BY ULTRAVIOLET SPECTROSCOPY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 1, Nov. 2019, pp. 180-3, doi:10.22159/ajpcr.2020.v13i1.36098.
Section
Original Article(s)